NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ: NAMS · HEALTHCARE · BIOTECHNOLOGY
$28.43
-1.01% today
Updated 2026-04-29
Market cap
$3.27B
P/E ratio
—
P/S ratio
145.26x
EPS (TTM)
$-1.72
Dividend yield
—
52W range
$17 – $42
Volume
0.9M
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $102.69M | $14.09M | $45.56M | $22.50M |
| Revenue growth (YoY) | — | — | — | -86.3% | +223.4% | -50.6% |
| Cost of revenue | — | $14558.00 | $70703.00 | $44394.00 | $113000.00 | $59000.00 |
| Gross profit | — | $-14558.00 | $102.69M | $14.09M | $45.56M | $22.44M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 99.7% |
| R&D | $4.94M | $28.97M | $86.74M | $159.42M | $151.41M | $141.83M |
| SG&A | $1.68M | $4.70M | $19.51M | $37.63M | $70.45M | $106.30M |
| Operating income | $-6.63M | $-34.98M | $-3.56M | $-182.97M | $-176.29M | $-225.68M |
| Operating margin | — | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
| EBITDA | $-6.63M | $-41.37M | $-22.34M | $-176.86M | $-241.49M | $-242.32M |
| EBITDA margin | — | — | -21.8% | -1255.2% | -530.0% | -1076.9% |
| EBIT | $-6.63M | $-41.37M | $-22.35M | $-176.91M | $-241.60M | $-242.54M |
| Interest expense | $344000.00 | $411000.00 | $287000.00 | $6.80M | $0.00 | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-7.02M | $-41.78M | $-22.63M | $-176.94M | $-241.60M | $-203.82M |
| Net income growth (YoY) | — | -495.0% | +45.8% | -681.7% | -36.5% | +15.6% |
| Profit margin | — | — | -22.0% | -1255.8% | -530.3% | -905.7% |